Needham & Company LLC Reaffirms Buy Rating for LivaNova (NASDAQ:LIVN)

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a report issued on Monday,Benzinga reports. They presently have a $75.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 47.96% from the company’s previous close.

Several other research analysts have also weighed in on the stock. Mizuho lowered their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. Robert W. Baird boosted their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, LivaNova currently has an average rating of “Buy” and an average price target of $69.17.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $50.69 on Monday. The company’s fifty day moving average is $52.18 and its two-hundred day moving average is $52.30. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The firm has a market capitalization of $2.75 billion, a P/E ratio of 120.69 and a beta of 1.01. LivaNova has a one year low of $42.75 and a one year high of $64.47.

Hedge Funds Weigh In On LivaNova

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in LivaNova by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock worth $102,537,000 after purchasing an additional 62,480 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of LivaNova in the first quarter valued at approximately $94,000. Lazard Asset Management LLC purchased a new position in shares of LivaNova during the first quarter valued at approximately $84,000. Price T Rowe Associates Inc. MD boosted its position in LivaNova by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock worth $1,736,000 after acquiring an additional 1,980 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in LivaNova during the first quarter worth approximately $397,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.